title: Serum omentin level in patients with prostate cancer.
abstract: Prostate cancer (PCa) is the second leading cause of cancer-related death in males. Hypertriglyceridemia and obesity are known risk factors for disease development. Omentin is a plasma adipokine that is synthesized in visceral adipose tissue; its plasma concentration changes in colorectal cancer and conditions associated with insulin resistance. To our knowledge, the relationship between omentin and PCa has not been investigated previously. Therefore, we evaluated omentin levels in PCa patients in this matched case-control study. Fifty consecutive patients newly diagnosed with PCa and 30 consecutive patients newly diagnosed with benign prostatic hyperplasia (BPH) were assessed. Patients with PCa were divided into three subgroups according to the Gleason score. The omentin concentrations were determined using enzyme-linked immunosorbent assays. Blood urea nitrogen (p < 0.001), creatinine (Cr; p < 0.001), total cholesterol (p < 0.001), low-density lipoprotein (p < 0.001), and prostate-specific antigen (PSA; p = 0.03) levels were significantly higher in the PCa group than the BPH group. The median omentin level in BPH patients was 373 (207-792) versus 546.8 (297.1-945.7) ng/mL in the PCa group (p < 0.001). There was a negative weak/moderate correlation between omentin and body mass index in the BPH group (r = -0.364, p = 0.048). Circulating omentin levels were elevated in patients with PCa. Further studies would be useful to establish the mechanism underlying this increase and to assess the interaction between PCa and adipose tissue.
authors.affiliation: Department of Urology, Faculty of Medicine, Abant Izzet Baysal University, Bolu, 14280, Turkey, uguruyeturk@yahoo.com.
authors.forename: Ugur
authors.initials: U
authors.lastname: Uyeturk
authors.forename: Hasmet
authors.initials: H
authors.lastname: Sarıcı
authors.forename: Buket
authors.initials: B
authors.lastname: Kın Tekce
authors.forename: Muzaffer
authors.initials: M
authors.lastname: Eroglu
authors.forename: Eray
authors.initials: E
authors.lastname: Kemahlı
authors.forename: Ummugul
authors.initials: U
authors.lastname: Uyeturk
authors.forename: Adnan
authors.initials: A
authors.lastname: Gucuk
mesh_terms: D000273:Adipose Tissue / Q000378:metabolism; D000328:Adult; D000368:Aged; D000886:Anthropometry; D001706:Biopsy; D001806:Blood Urea Nitrogen; D015992:Body Mass Index; D016022:Case-Control Studies; D002784:Cholesterol / Q000097:blood; D003404:Creatinine / Q000097:blood; D016207:Cytokines / Q000097:blood*; D058851:GPI-Linked Proteins / Q000097:blood; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D037102:Lectins / Q000097:blood*; D008077:Lipoproteins, LDL / Q000097:blood; D008297:Male; D008875:Middle Aged; D011467:Prostate / Q000378:metabolism; D017430:Prostate-Specific Antigen / Q000378:metabolism; D011470:Prostatic Hyperplasia / Q000097:blood* / Q000378:metabolism*; D011471:Prostatic Neoplasms / Q000097:blood* / Q000378:metabolism*; D016896:Treatment Outcome
chemical_list: D016207:Cytokines; D058851:GPI-Linked Proteins; C432397:ITLN1 protein, human; D037102:Lectins; D008077:Lipoproteins, LDL; D002784:Cholesterol; D003404:Creatinine; D017430:Prostate-Specific Antigen